Scholar Rock to Announce Q4 Earnings on March 2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SRRK?
Source: seekingalpha
- Earnings Announcement: Scholar Rock is set to announce its Q4 earnings on March 2 after market close, with consensus EPS estimate at -$0.88 and revenue estimate at $0M, indicating ongoing challenges in profitability.
- EPS Estimate Changes: Over the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting cautious optimism among analysts regarding the company's future performance despite the overall negative outlook.
- Conference Presentation: Scholar Rock presented at the 44th Annual J.P. Morgan Healthcare Conference, which has heightened market interest in its product pipeline, particularly the forward path for Apitegromab.
- Rating Maintenance: Despite challenges, Seeking Alpha maintains a “Buy” rating on Scholar Rock, indicating confidence in its long-term potential, especially with ongoing investments in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRRK
Wall Street analysts forecast SRRK stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.270
Low
42.00
Averages
50.00
High
60.00
Current: 44.270
Low
42.00
Averages
50.00
High
60.00
About SRRK
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scholar Rock to Announce Q4 Earnings on March 2
- Earnings Announcement: Scholar Rock is set to announce its Q4 earnings on March 2 after market close, with consensus EPS estimate at -$0.88 and revenue estimate at $0M, indicating ongoing challenges in profitability.
- EPS Estimate Changes: Over the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting cautious optimism among analysts regarding the company's future performance despite the overall negative outlook.
- Conference Presentation: Scholar Rock presented at the 44th Annual J.P. Morgan Healthcare Conference, which has heightened market interest in its product pipeline, particularly the forward path for Apitegromab.
- Rating Maintenance: Despite challenges, Seeking Alpha maintains a “Buy” rating on Scholar Rock, indicating confidence in its long-term potential, especially with ongoing investments in the biopharmaceutical sector.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation
- Share Acquisition: Redmile Group disclosed a purchase of 1,316,390 shares of Scholar Rock Holding Corporation in an SEC filing dated February 17, 2026, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, highlighting its significance in the fund's asset management and reinforcing its investment strategy in the biopharmaceutical sector.
- Market Performance: As of February 17, 2026, Scholar Rock's shares were priced at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, suggesting positive market expectations regarding its product development.
- Financial Position: Scholar Rock has a market capitalization of $4.78 billion, and while it reported a net income of -$353.43 million, its cash reserves of approximately $365 million provide a buffer for future growth, reducing near-term dilution risk and attracting long-term investors.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
- Share Acquisition: Redmile Group disclosed in an SEC filing on February 17, 2026, that it purchased 1,316,390 shares of Scholar Rock Holding Corporation, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, representing 16.9% of the fund's 13F reportable assets, further solidifying its investment position in the biopharmaceutical sector.
- Strong Market Performance: As of February 17, 2026, Scholar Rock's share price stood at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, showcasing market recognition of its growth potential.
- Robust Financial Position: Scholar Rock reported approximately $365 million in cash as of December 31, 2026, projected to sustain operations into 2027, thereby reducing near-term dilution risk and providing confidence for long-term investors.
See More
Scholar Rock Grants Equity Awards to New Employees
- Equity Incentive Plan: Scholar Rock has granted a total of 114,668 shares in equity awards to seven new employees, comprising 64,226 shares in stock options and 50,442 shares in restricted stock units, aimed at attracting high-quality talent to the company.
- Option Exercise Price: The granted stock options have an exercise price of $47.85 per share, matching the closing price on February 9, 2026, a strategy that helps align employee incentives with market performance and enhances long-term motivation.
- Vesting Schedule: 25% of the stock options will vest on the first anniversary of each employee's start date, with the remaining 75% vesting in 12 equal quarterly installments, while the restricted stock units will vest in four equal annual installments, ensuring continued employee service.
- Company Background: Scholar Rock focuses on developing treatments for spinal muscular atrophy and other rare neuromuscular diseases, leveraging its proprietary platform in muscle growth factor modulation to create new therapeutic possibilities for patients.
See More
Scholar Rock Executive Sells Shares, Investor Implications
- Executive Stock Sale: On January 22, 2026, Scholar Rock's Chief Scientific Officer Mo Qatanani sold 14,898 shares for approximately $695,937, indicating executive activity in the market and raising investor interest in the company's future performance.
- Ownership Proportion Change: Following this transaction, Qatanani's direct ownership decreased to 85,660 shares, representing only 21% of total holdings, which may affect investor confidence in his commitment to the company's future.
- Trading Plan Context: The stock sale was executed under a Rule 10b5-1 trading plan, indicating that the transaction was pre-scheduled rather than a spontaneous decision, which mitigates potential negative interpretations of insider selling.
- Future Product Outlook: Scholar Rock plans to launch its key product candidate, apitegromab, in 2026, and if approved by the FDA and other global agencies, it could significantly enhance the company's market position in treating spinal muscular atrophy, thereby increasing its investment appeal.
See More
Scholar Rock Executive Sells Shares
- Share Sale Transaction: Mo Qatanani, Chief Scientific Officer of Scholar Rock, sold 14,898 shares on January 22, 2026, for approximately $695,938 at a weighted average price of $46.71 per share, representing a 14.82% reduction in his direct holdings, leaving him with 85,660 shares, or 0.08% of the outstanding shares.
- Trading Plan Context: The sale was executed under a Rule 10b5-1 trading plan, indicating that it was not a voluntary action by Qatanani but rather a pre-scheduled transaction designed to ensure compliance and mitigate insider trading risks.
- Future Product Plans: Scholar Rock aims to launch its key product candidate, apitegromab, in the U.S. and European markets in 2026, which is touted as the world's first muscle-targeted treatment for spinal muscular atrophy (SMA); success in this endeavor could significantly enhance the company's market outlook.
- Financial Status and Market Performance: Despite only a 2% stock increase in 2025 and ongoing net losses, the potential success of the apitegromab project could make SRRK a more attractive investment option, likely drawing increased investor interest.
See More
Scholar Rock to Announce Q4 Earnings on March 2
- Earnings Announcement: Scholar Rock is set to announce its Q4 earnings on March 2 after market close, with consensus EPS estimate at -$0.88 and revenue estimate at $0M, indicating ongoing challenges in profitability.
- EPS Estimate Changes: Over the last three months, there has been one upward revision and no downward adjustments to EPS estimates, reflecting cautious optimism among analysts regarding the company's future performance despite the overall negative outlook.
- Conference Presentation: Scholar Rock presented at the 44th Annual J.P. Morgan Healthcare Conference, which has heightened market interest in its product pipeline, particularly the forward path for Apitegromab.
- Rating Maintenance: Despite challenges, Seeking Alpha maintains a “Buy” rating on Scholar Rock, indicating confidence in its long-term potential, especially with ongoing investments in the biopharmaceutical sector.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation
- Share Acquisition: Redmile Group disclosed a purchase of 1,316,390 shares of Scholar Rock Holding Corporation in an SEC filing dated February 17, 2026, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, highlighting its significance in the fund's asset management and reinforcing its investment strategy in the biopharmaceutical sector.
- Market Performance: As of February 17, 2026, Scholar Rock's shares were priced at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, suggesting positive market expectations regarding its product development.
- Financial Position: Scholar Rock has a market capitalization of $4.78 billion, and while it reported a net income of -$353.43 million, its cash reserves of approximately $365 million provide a buffer for future growth, reducing near-term dilution risk and attracting long-term investors.
See More
Redmile Group Increases Stake in Scholar Rock Holding Corporation by $49 Million
- Share Acquisition: Redmile Group disclosed in an SEC filing on February 17, 2026, that it purchased 1,316,390 shares of Scholar Rock Holding Corporation, with an estimated transaction value of $49.37 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Redmile Group's stake in Scholar Rock rises to 16.94%, representing 16.9% of the fund's 13F reportable assets, further solidifying its investment position in the biopharmaceutical sector.
- Strong Market Performance: As of February 17, 2026, Scholar Rock's share price stood at $46.45, reflecting a 25.7% increase over the past year, outperforming the S&P 500 by 13.39 percentage points, showcasing market recognition of its growth potential.
- Robust Financial Position: Scholar Rock reported approximately $365 million in cash as of December 31, 2026, projected to sustain operations into 2027, thereby reducing near-term dilution risk and providing confidence for long-term investors.
See More
Scholar Rock Grants Equity Awards to New Employees
- Equity Incentive Plan: Scholar Rock has granted a total of 114,668 shares in equity awards to seven new employees, comprising 64,226 shares in stock options and 50,442 shares in restricted stock units, aimed at attracting high-quality talent to the company.
- Option Exercise Price: The granted stock options have an exercise price of $47.85 per share, matching the closing price on February 9, 2026, a strategy that helps align employee incentives with market performance and enhances long-term motivation.
- Vesting Schedule: 25% of the stock options will vest on the first anniversary of each employee's start date, with the remaining 75% vesting in 12 equal quarterly installments, while the restricted stock units will vest in four equal annual installments, ensuring continued employee service.
- Company Background: Scholar Rock focuses on developing treatments for spinal muscular atrophy and other rare neuromuscular diseases, leveraging its proprietary platform in muscle growth factor modulation to create new therapeutic possibilities for patients.
See More
Scholar Rock Executive Sells Shares, Investor Implications
- Executive Stock Sale: On January 22, 2026, Scholar Rock's Chief Scientific Officer Mo Qatanani sold 14,898 shares for approximately $695,937, indicating executive activity in the market and raising investor interest in the company's future performance.
- Ownership Proportion Change: Following this transaction, Qatanani's direct ownership decreased to 85,660 shares, representing only 21% of total holdings, which may affect investor confidence in his commitment to the company's future.
- Trading Plan Context: The stock sale was executed under a Rule 10b5-1 trading plan, indicating that the transaction was pre-scheduled rather than a spontaneous decision, which mitigates potential negative interpretations of insider selling.
- Future Product Outlook: Scholar Rock plans to launch its key product candidate, apitegromab, in 2026, and if approved by the FDA and other global agencies, it could significantly enhance the company's market position in treating spinal muscular atrophy, thereby increasing its investment appeal.
See More
Scholar Rock Executive Sells Shares
- Share Sale Transaction: Mo Qatanani, Chief Scientific Officer of Scholar Rock, sold 14,898 shares on January 22, 2026, for approximately $695,938 at a weighted average price of $46.71 per share, representing a 14.82% reduction in his direct holdings, leaving him with 85,660 shares, or 0.08% of the outstanding shares.
- Trading Plan Context: The sale was executed under a Rule 10b5-1 trading plan, indicating that it was not a voluntary action by Qatanani but rather a pre-scheduled transaction designed to ensure compliance and mitigate insider trading risks.
- Future Product Plans: Scholar Rock aims to launch its key product candidate, apitegromab, in the U.S. and European markets in 2026, which is touted as the world's first muscle-targeted treatment for spinal muscular atrophy (SMA); success in this endeavor could significantly enhance the company's market outlook.
- Financial Status and Market Performance: Despite only a 2% stock increase in 2025 and ongoing net losses, the potential success of the apitegromab project could make SRRK a more attractive investment option, likely drawing increased investor interest.
See More
